List of works - Lawrence Blonde

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

scientific article published on 29 July 2019

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study

scientific article published on 5 December 2017

Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study

scientific article published on 25 June 2018

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo

scientific article published on 20 August 2020

Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations

scientific article published on 18 May 2018

Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations

scientific article published on 01 July 2018

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison

scientific article published on 06 July 2020

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study

scientific article published on 05 April 2019

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study

scientific article published on 09 September 2020

Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial

scientific article published on 23 April 2020

Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial

scientific article published on 15 June 2020

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis

scientific article published on 22 July 2020

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

scientific article published on 24 October 2018

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

scientific article published on 27 January 2020

Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.

scientific article published on 14 March 2018

Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences

scientific article published on 01 February 2020

Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin.

scientific article published on 22 December 2017

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

scientific article published on 17 September 2019

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)

scientific article published on 18 July 2019

List of works by Lawrence Blonde